Analyst firms · UBS · LLY
UBS LLY price target and rating history
Eli Lilly and Company (LLY) · Health Care
UBS rates Eli Lilly and Company (LLY) Buy with a $1,250 price target, as of its latest action on Jan 7, 2026. It has published 4 rating actions on LLY since September 2022, including 1 upgrade and 0 downgrades. Across 10 firms with a LLY price target in the last 12 months, the median target is $1,240. UBS's $1,250 is 1% above that.
- Current rating
- Buy
- Price target
- $1,250
- Median target, all firms
- $1,240
- Actions on LLY
- 4
UBS price target on LLY
Every UBS rating on LLY
- Jan 7, 2026
- Oct 20, 2023
- May 24, 2023
- Sep 22, 2022
How other firms rate LLY
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Berenberg | Buy | $1,400 | Sep 15, 2026 |
| HSBC | Reduce | $850 | Mar 17, 2026 |
| RBC Capital Markets | Outperform | $1,250 | Feb 25, 2026 |
| Barclays | Overweight | $1,350 | Feb 20, 2026 |
| UBS | Buy | $1,250 | Jan 7, 2026 |
| Daiwa | Buy | $1,230 | Dec 16, 2025 |
| Goldman Sachs | Buy | $1,145 | Dec 15, 2025 |
| BofA Securities | Buy | $1,268 | Dec 15, 2025 |
| Scotiabank | Sector Outperform | $1,165 | Nov 13, 2025 |
| Leerink Partners | Outperform | $1,104 | Nov 10, 2025 |
Questions about UBS and LLY
- What is UBS's price target for LLY?
- UBS's latest stated price target for Eli Lilly and Company (LLY) is $1,250, from its action on Jan 7, 2026.
- What is UBS's rating on LLY?
- UBS rates LLY Buy, a bullish rating, as of Jan 7, 2026.
- When did UBS last change its view on LLY?
- On Jan 7, 2026, UBS resumes coverage at Buy, price target $1,250.
- How does UBS's LLY target compare with other analysts?
- Across 10 firms with a LLY price target in the last 12 months, the median target is $1,240. UBS's $1,250 is 1% above that.
More LLY rating histories
- Berenberg4
- HSBC4
- Barclays3
- Daiwa4
- BofA Securities4
- Leerink Partners3
- BMO Capital Markets3
- Citigroup3
- DZ Bank3
- Morgan Stanley6
- Wells Fargo3
All UBS ratingsLLY news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.